D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target

Benzinga · 10/31/2025 11:51
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.